Articles
Cardiovascular prevention is better than a cure

Cardiovascular prevention is better than a cure

Is it in pharma’s best interest to help with cardiovascular disease prevention? In our latest interview, Professor Neil Poulter explains how it might well be. With limited early warning signs and increasingly poor diets and lifestyles, cardiovascular disease has become a real public health issue...

Articles
What Are IDEAs Made Of: Enemy of innovation - The TPP

What Are IDEAs Made Of: Enemy of innovation - The TPP

With a decline in productivity within the industry, Mike Rea questions whether it's the Target Product Profile that is holding back innovation. The industry has a well-recognised problem. There is a prevailing view that developing drugs is hard, and that attrition is...

Articles
Four cornerstones of successful patient engagement (part II)

Four cornerstones of successful patient engagement (part II)

In the second of his two part series on patient engagement Mat Phillips highlights the essentials to building valuable and legitimate relationships with patients. There is still a long way to go before patients are fully engaged with the decisions that affect their own health, and the…

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Editor's Picks

  1. UK budget includes £1bn biopharma investment package
  2. HHS doubles down on controversial peptides plan
  3. Lilly's triple G overpowers Ozempic in diabetes trial
  4. UK puts £100m into "world-first" AI biosecurity facility
  5. US gives $99m for Ebola jab project, as cases spread in Africa

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more